INF 101Alternative Names: INF-101; OX-1001
Latest Information Update: 30 Sep 2016
At a glance
- Originator OncoNOX
- Developer Inflamalps
- Mechanism of Action Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry eyes; Uveitis
Most Recent Events
- 02 Aug 2016 Preclinical trials in Dry eyes in Switzerland (Topical)
- 02 Aug 2016 Preclinical trials in Uveitis in Switzerland (Topical)